REVIEW ARTICLE

MEDICAL PROGRESS

Atypical Hemolytic–Uremic Syndrome

Marina Noris, Ph.D., and Giuseppe Remuzzi, M.D.

From the Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research (M.N., G.R.), and the Division of Nephrology and Dialysis, Ospedali Riuniti di Bergamo (G.R.) — both in Bergamo, Italy. Address reprint requests to Dr. Remuzzi at the Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy, or at gremuzzi@ marionegri.it.

N Engl J Med 2009;361:1676-87. Copyright © 2009 Massachusetts Medical Society. The HEMOLYTIC-UREMIC SYNDROME IS CHARACTERIZED BY NONIMMUNE hemolytic anemia, thrombocytopenia, and renal impairment.¹ The disorder occurs most frequently in children under the age of 5 years, with an annual incidence of 6.1 cases per 100,000 children under 5 years, as compared with an overall incidence of 1 to 2 cases per 100,000. The presentation is generally heralded by diarrhea, which is often bloody.^{2,3} Most cases (including more than 90% of those in children) are secondary to infection with *Escherichia coli* serotypes O157:H7, O111:H8, O103:H2, O123, O26, or others,¹ which produce Shiga-like toxin (Stx), and several other bacteria, such as *Streptococcus pneumoniae*.⁴

Approximately 10% of cases of the hemolytic–uremic syndrome are classified as atypical, since they are not caused by either Stx-producing bacteria or streptococci.^{1,5} Atypical hemolytic–uremic syndrome has a poor prognosis, with death rates as high as 25%⁵ and progression to end-stage renal disease in half the patients.^{1,4} Research has linked atypical hemolytic–uremic syndrome to uncontrolled activation of the complement system. This article reviews current concepts about the pathobiology of this syndrome and its diagnosis and management.

THE HISTOLOGIC LESION

The lesions of Stx-related hemolytic–uremic syndrome, which are indistinguishable from those of its atypical form on the basis of standard histologic analysis, are characterized by thickening of arterioles and capillaries, endothelial swelling and detachment, and subendothelial accumulation of proteins and cell debris (Fig. 1).^{6,7} The subendothelial space is widened, and platelet thrombi obstruct vessel lumina. Hemolysis occurs, and fragmented or distorted erythrocytes are evident in blood smears. Lesions typically affect the kidney (mainly glomeruli and arterioles), although the brain, heart, lungs, gastrointestinal tract, and pancreas all may be involved.

CLASSIFICATION OF DISEASE

FAMILIAL FORM

Less than 20% of cases of atypical hemolytic–uremic syndrome are familial (Table 1). Patients with the familial form of the disease have a poor prognosis, with a rate of either end-stage renal disease or death of 50 to 80%. In 1965, a combination of hemolytic anemia and azotemia was described in concordant monozygous twins.⁸ Since that time, familial atypical hemolytic–uremic syndrome has been reported in children and, infrequently, in adults. Both autosomal dominant and recessive patterns of inheritance have been reported.⁹

SPORADIC FORM

Atypical hemolytic–uremic syndrome that develops in patients who do not have a family history of the disease is classified as sporadic. Triggers for the sporadic form

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

include infection with the human immunodeficiency virus, cancer, organ transplantation, pregnancy, and the use of certain anticancer drugs, immunotherapeutic agents (e.g., cyclosporine and tacrolimus), and antiplatelet agents (e.g., ticlopidine and clopidogrel).^{2,6,10}

De novo atypical hemolytic–uremic syndrome has been reported in 3.6 to 14.0% of all kidneytransplant recipients in association with humoral rejection and the use of calcineurin inhibitors.¹¹⁻¹³ In approximately 10 to 15% of female patients with atypical hemolytic–uremic syndrome, the disorder develops during pregnancy or post partum.^{1,2} Approximately 50% of sporadic cases appear to be idiopathic.

Genetic abnormalities in complement system proteins have been documented in the familial form of the disease¹⁴⁻¹⁸ and also in the sporadic (mainly idiopathic) form (Table 1).^{14,19-21} Two patients with Stx-related hemolytic–uremic syndrome have been reported to have mutations in complement regulatory genes,^{20,22} but the frequency of the mutations in such patients is not known.

COMPLEMENT ABNORMALITIES

Since 1974, reduced serum levels of complement fraction C3 with normal levels of C4 have been reported in patients with atypical hemolytic–uremic syndrome.²³⁻²⁵ A low C3 level reflects complement activation and consumption (Fig. 2). Patients with the hemolytic–uremic syndrome who have low C3 levels have high levels of activated complement components, including C3b, C3c, and C3d.²⁶ Granular C3 deposits in glomeruli and arterioles during acute disease are consistent with the activation of complement and local C3 consumption.^{24,27} C9 staining in glomeruli and small arteries with intimal proliferation and thrombosis documents activation up to the final lytic C5b-9 membrane-attack complex.²⁸

The complement system consists of several plasma and membrane-bound proteins that protect against invading organisms.²⁹ Three activation pathways — classic, lectin, and alternative — produce protease complexes termed C3 and C5 convertases that cleave C3 and C5, respectively, eventually leading to the membrane-attack complex (Fig. 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). C3 hydrolysis in plasma initiates the alternative pathway, leading to the deposition of C3b onto practically all plasma-exposed surfaces (Fig. 2A).³⁰

On host cells, complement activation is controlled by both membrane-anchored and fluid-phase regulators, favoring the cleavage of C3b to inactive C3b (iC3b) by complement factor I (CFI) (i.e., cofactor activity) and dissociating the multicomponent C3 and C5 convertases (i.e., decay-acceleration activity). Without normal regulation, C3b deposition increases by more than a factor of 2030 through the amplification loop and causes activation of the complement cascade, which remains so until complement components are consumed. Foreign targets and injured cells that either do not have membrane-bound regulators or cannot bind soluble regulators are attacked by complement. On the surface of bacteria, C3b binds to specific receptors on neutrophils and macrophages, resulting in phagocytosis of complement-tagged bacteria.

The C3 convertases of the classic and lectin pathways are formed by C2 and C4 fragments, whereas the alternative pathway convertase cleaves C3 but not C4.²⁹ Thus, a low serum C3 level in a patient with atypical hemolytic–uremic syndrome who has a normal C4 level indicates selective activation of the alternative pathway.²⁵

GENETIC ABNORMALITIES

COMPLEMENT PATHWAY MUTATIONS

A variety of mutations in members of the complement pathway have been described in patients with atypical hemolytic–uremic syndrome. These mutations have been found to account for 50 to 60% of cases (Table 2, and Fig. 2 in the Supplementary Appendix).

COMPLEMENT FACTOR H

In 1981, investigators described two brothers with atypical hemolytic-uremic syndrome who did not produce complement factor H (CFH), the plasma regulator of the alternative pathway.³¹ The parents, who were first cousins, had half-normal CFH levels, indicating an inherited defect. Subsequently, complete or partial CFH deficiencies have been reported in patients with atypical hemolytic-uremic syndrome.^{25,32} In 1998, a group of investigators headed by Goodship (Warwicker et al.33) showed an association between atypical hemolyticuremic syndrome and the chromosome 1g32 locus, which contains genes for CFH and other complement regulators. The investigators found a heterozygous CFH mutation in patients with the syndrome and obligate carriers in one family and

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.



Figure 1. Micrographs of Samples from Patients with Atypical Hemolytic–Uremic Syndrome.

Panels A and B show light micrographs of glomeruli from a patient with a heterozygous complement factor H (*CFH*) mutation. In Panel A, intracapillary thrombosis, congestion, and thickening of the capillary wall are clearly visible (Masson's trichrome). In Panel B, there is marked glomerular retraction and wrinkling of the capillary tuft (silver stain). Panel C shows renal arterioles from a patient with a heterozygous complement factor I (*CFI*) mutation. An arteriole shows endothelial swelling and hyperplasia with narrowing of the lumen (arrow), and the lumen of another vessel is occluded (arrowhead) (periodic acid–Schiff). Panel D shows an electron micrograph of the glomerular capillary wall in a sample from a patient with a heterozygous *C3* mutation. The endothelium (arrow) is detached from the glomerular basement membrane. The subendothelial space (arrowhead) is widened and occupied by electron-lucent fluffy material and cell debris, with a marked narrowing of the capillary lumen. Podocyte foot processes are focally effaced (uranyl acetate–osmium tetroxide).

another heterozygous mutation in a patient with a sporadic form of the disease, which suggested that sporadic forms of the syndrome had a genetic basis.

CFH POINT MUTATIONS

More than 80 mutations in *CFH* have been identified in patients with atypical hemolytic–uremic syndrome, with a mutation frequency of 40 to 45% in patients with the familial form and of 10 to 20% in those with the sporadic form.^{14,34-38} (Details about mutations in atypical hemolytic– uremic syndrome are available at www.FH-HUS. org.) CFH, a plasma protein containing 20 homologous repeats, regulates the alternative pathway by competing with complement factor B (CFB) for C3b recognition by acting as a cofactor for CFI and by enhancing dissociation of C3 convertase (Fig. 2A and 2B).³⁹ These functions are located in the N-terminal region of CFH. In addition, CFH binds to glycosaminoglycans in basement membranes and endothelium through its C-terminal repeats.⁴⁰ CFH down-regulates alternative-pathway activation on structures without other complement regulators, such as glomerular basement membranes, and contributes to endothelial protection when membrane-bound regulators are present.

N ENGLJ MED 361;17 NEJM.ORG OCTOBER 22, 2009

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

The vast majority of CFH mutations in patients with atypical hemolytic-uremic syndrome are heterozygous and cluster mainly in the C-terminal, causing amino acid changes or translation interruption (Fig. 2 in the Supplementary Appendix). With this abnormality there is a lower density of mutant CFH on cell surfaces and diminished cofactor activity for C3b degradation because of low binding of mutant CFH to glycosaminoglycans on endothelial cells or to surface-bound C3b.40-42 Lysis of sheep erythrocytes is a standard test of this system, since these cells have surface glycosaminoglycans and bind CFH. At variance with normal serum, serum from patients with CFH mutations lyses sheep erythrocytes through the alternative pathway. The addition of normal CFH stops this lysis (Fig. 2B).43

Most mutant forms of CFH are secreted in plasma. Since CFH forms oligomers,^{44,45} in plasma from heterozygous patients mutant CFH seems to interact with normal CFH and impairs its binding to endothelial cells, suggesting a dominant negative effect,⁴² in which the abnormal gene product acts to block the effect of the wild-type allele. Therefore, even though 50% of CFH molecules are normal, they are not sufficient for preventing atypical hemolytic–uremic syndrome. Homozygous CFH mutations, which account for only 15 to 20% of CFH mutations in patients with this syndrome, lead to quantitative CFH deficiency and very low C3 levels.³⁵

GENOMIC ABNORMALITIES

A high degree of sequence identity between *CFH* and genes encoding five complement factor H–related proteins (*CFHR1* through *CFHR5*), which are located in tandem to *CFH*, may predispose to non-allelic recombinations.⁴⁶ In 3 to 5% of patients with atypical hemolytic–uremic syndrome, a heterozygous hybrid gene deriving from an uneven cross-over between *CFH* and *CFHR1* (which contains the first 21 *CFH* exons and the last two *CFHR1* exons⁴⁷) results in a gene product with decreased complement regulatory activity on endothelial surfaces.

AUTOANTIBODIES AGAINST CFH

In approximately 6 to 10% of patients with atypical hemolytic–uremic syndrome, anti-CFH autoantibodies develop.⁴⁸⁻⁵⁰ These antibodies bind to the CFH C-terminal, reduce CFH binding to C3b, and enhance alternative-pathway–dependent lysis of sheep erythrocytes without influencing fluid-phase

Table 1. Classification of Atypical Hemolytic–Uremic Syndrome.*					
Form of Disease	Complement Abnormalities				
Familial	Mutations in CFH, 40–45%; in CFI, 5–10%; in C3, 8–10%; in MCP, 7–15%; in THBD, 9%; and in CFB, 1–2%.				
Sporadic					
Idiopathic	Mutations in CFH, 15–20%; in CFI, 3–6%; in C3, 4–6%; in MCP, 6–10%; in THBD, 2%; and in CFB, 2 cases; anti-CFH antibodies: 6–10%				
Pregnancy-associated	Mutations in CFH, 20%; in CFI, 15%				
HELLP syndrome	Mutations in CFH, 10%; in CFI, 20%; and in MCP, 10%				
Drugs	Rare CFH mutations (mostly unknown)				
Organ transplantation	Mutations in CFH, 15%; in CFI, 16%				
Human immunodeficiency virus infection	Unknown†				
Cancer	Unknown†				

* HELLP denotes hemolytic anemia, elevated liver enzymes, and low platelet count.

† There are no published data on the frequency of complement gene mutations or anti-CFH autoantibodies in patients with this condition.

cofactor activity.51 The lack of complement control on cells, despite control in the fluid phase, mimics the course of the disease in patients with CFH mutations. Anti-CFH autoantibodies develop mainly in young children who, unlike their heterozygous mothers, lack CFHR1 and CFHR3 because of homozygous deletions of the corresponding genes.^{50,52,53} Interestingly, the antibodies appear to recognize CFHR1 and CFHR3,50 which suggests that they may arise from an immune reaction against maternal CFHR1 and CFHR3 (Dragon-Durey MA: personal communication). CFHR1/3 deficiency itself may also predispose to atypical hemolytic-uremic syndrome, since patients with this deficiency who do not have anti-CFH antibodies have been described previously.53,54

MEMBRANE COFACTOR PROTEIN

Mutations in the gene encoding membrane cofactor protein (MCP), a widely expressed transmembrane regulator, have been described in 10 to 15% of patients with atypical hemolytic–uremic syndrome.¹⁴⁻¹⁶ MCP serves as a cofactor for CFI to cleave C3b and C4b on cell surfaces (Fig. 2A and 2B).⁵⁵ Intact MCP is pivotal in preventing C3 activation on glomerular endothelium. In one study, an anti-MCP antibody completely blocked cofactor

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.



Figure 2. Model for the Mechanisms Leading from Impaired Regulation of the Alternative Pathway to Thrombotic Microangiopathy.

In a normal endothelial cell (Panel A), complement factor H (CFH) binds to the endothelial surface and to C3b and together with membrane cofactor protein (MCP) acts as a cofactor for cleavage of C3b, which is mediated by complement factor I (CFI), a process that prevents its interaction with factor B. CFH also dissociates the C3 convertase of the alternative pathway (C3b). Thrombomodulin (TM) enhances CFI-mediated inactivation of C3b in the presence of CFH and promotes activation of the thrombin-activatable fibrinolysis inhibitor (TAFIa), which degrades C3a and C5a. In patients with loss-of-function mutations in complement regulatory genes (CFH, CFI, MCP, and THBD [the gene encoding thrombomodulin]) (Panel B), C3b is not degraded efficiently and forms the C3 and C5 convertases of the alternative pathway. Mutated TM cannot inactivate C5a and C3a because of reduced formation of TAFIa. C5b initiates the assembly of the membrane-attack complex (MAC), leading to cell injury and activation, with expression of adhesion molecules, which together with C3a and C5a recruit and activate leukocytes. Subsequent cell detachment results in a prothrombotic state. Aggregated platelets release procoagulant platelet-derived microparticles (PMP), which facilitate the assembly of clotting enzymes. A similar situation applies to patients with gain-of-function mutations in CFB and C3. Mutant CFB forms a superconvertase that is resistant to dissociation by CFH. Mutant C3b does not bind CFH and MCP and is resistant to degradation by CFI. GAG denotes glycosaminoglycans.

> activity in cell extracts.⁵⁶ Most mutations are kocytes was reduced in 75% of mutants. Other mozygous or compound heterozygous. Such mu- decreased cofactor activity.14,57 tations usually cluster in extracellular domains that are critical for regulation (Fig. 2 in the Sup- CFI plementary Appendix). Expression on blood leu- CFI is a plasma serine protease that regulates the

> heterozygous, though about 25% are either ho- mutants showed low C3b-binding capability and

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

Table 2. Genetic Abnormalities and Clinical Outcome in Patients with Atypical Hemolytic-Uremic Syndrome.*							
Gene	Protein Affected	Main Effect	Frequency	Response to Short-Term Plasma Therapy†	Long-Term Outcome‡	Outcome of Kidney Transplantation	
			%				
CFH	Factor H	No binding to endothelium	20–30	Rate of remission: 60% (dose and timing depen- dent)	Rate of death or ESRD: 70–80%	Rate of recurrence: 80–90%∬	
CFHR1/3	Factor HR1, R3	Anti-factor H anti- bodies	6	Rate of remission: 70–80% (plasma exchange com- bined with im- munosuppres- sion)	Rate of ESRD: 30– 40%	Rate of recurrence: 20%¶	
МСР	Membrane cofactor protein	No surface expression	10–15	No definitive indica- tion for therapy	Rate of death or ESRD: <20%	Rate of recurrence: 15–20%¶	
CFI	Factor I	Low level or low cofactor activity	4–10	Rate of remission: 30–40%	Rate of death or ESRD: 60–70%	Rate of recurrence: 70–80%∬	
CFB	Factor B	C3 convertase stabi- lization	1–2	Rate of remission: 30%	Rate of death or ESRD: 70%	Recurrence in one case	
C3	Complement C3	Resistance to C3b inactivation	5–10	Rate of remission: 40–50%	Rate of death or ESRD: 60%	Rate of recurrence: 40–50%	
THBD	Thrombomodulin	Reduced C3b inacti- vation	5	Rate of remission: 60%	Rate of death or ESRD: 60%	Recurrence in one case	

* ESRD denotes end-stage renal disease.

† Remission was defined as either complete remission or partial remission (i.e., hematologic remission with renal sequelae).

The long-term outcome was defined as the outcome 5 to 10 years after onset.

§ Patients in this category were eligible for combined liver and kidney transplantation.

¶ Patients in this category were eligible for single kidney transplantation.

three complement pathways by cleaving C3b and C4b in the presence of cofactor proteins (Fig. 2A). *CFI* mutations affect 4 to 10% of patients with atypical hemolytic–uremic syndrome.^{14,58-60} All mutations identified to date have been heterozygous, and 80% cluster in the serine protease domain (Fig. 2 in the Supplementary Appendix). Approximately 50% of mutations result in low CFI levels.^{14,58-60} Others disrupt cofactor activity.⁵⁹

CFB AND C3

Gain-of-function mutations can affect genes encoding the alternative pathway C3 convertase components, CFB and C3 (Fig. 2A).^{17,18} *CFB* mutations, which lead to chronic alternative-pathway activation, occur in only 1 to 2% of patients with atypical hemolytic–uremic syndrome (Fig. 2 in the Supplementary Appendix).¹⁷ Mutants have excess C3b affinity and form a hyperactive C3 convertase that is resistant to dissociation, enhancing C3b formation.¹⁷

About 4 to 10% of patients have heterozygous mutations in *C3*, usually with low C3 levels.¹⁸ Most

mutations reduce C3b binding to CFH and MCP, which severely impairs degradation of mutant C3b (Fig. 2B).¹⁸

THROMBOMODULIN

A recent study has shown that about 5% of patients with atypical hemolytic–uremic syndrome carry heterozygous mutations in *THBD*, the gene encoding thrombomodulin, a membrane-bound anticoagulant glycoprotein that facilitates complement inactivation by CFI in the presence of CFH (Fig. 2A).⁶¹ Cells expressing these variants are less efficient in degrading C3b and in generating activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a plasma carboxypeptidase B that cleaves C3a and C5a (Fig. 2A and 2B).⁶¹

INCOMPLETE GENETIC PENETRANCE

Mutations in complement genes confer a predisposition rather than cause atypical hemolytic– uremic syndrome, and penetrance among carriers of *CFH*, *MCP*, and *CFI* mutations appears to be

1681

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

40 to 50%.¹⁴ Healthy carriers of *CFB* and *C3* mutations also have been reported.^{17,18} Thus, the presence of these mutations cannot be used to predict future cases of the syndrome.

About 5% of patients have combined mutations, usually in CFH with either MCP or CFI, each inherited from a healthy parent.14 In some family pedigrees, atypical hemolytic-uremic syndrome has occurred in family members with a CFH mutation on one allele and two or three predisposing CFH polymorphisms on the other allele, whereas the syndrome has not developed in family members carrying just one affected allele.³⁷ Similarly, in a large pedigree with CFI and MCP mutations and the risk-associated MCPggaac haplotype, the syndrome occurred only in family members who had all the risk factors.⁶² In another study,⁶³ carriers of a common CFH mutation that is associated with the hemolytic-uremic syndrome had disease penetrance of 30%, and most patients also carried at least one additional genetic risk factor. These data indicate that the concurrence of both mutations and risk polymorphisms may be required for the development of the syndrome.

Even in patients with multiple genetic risk factors, the syndrome may not occur until middle age, which suggests an environmental effect. Infections may precede clinical cases of the hemolytic–uremic syndrome in many such patients, including in 35% of those with mutant *CFH*, in 50% of those with mutant *MCP*, in 55% of those with mutant *CFI*, and in 22% of those with mutant *C3.*¹⁴ Pregnancy and the use of contraceptive pills were reported to trigger disease in 8% of patients with *CFH* mutations and in 20% of those with *CFI* mutations.¹⁴

Given such data, unaffected carriers should be monitored during pregnancy and episodes of infection, and precipitants, such as drugs that trigger the hemolytic–uremic syndrome, should be avoided.

FROM COMPLEMENT ABNORMALITIES TO THROMBOTIC MICROANGIOPATHY

Several factors that contribute to complement regulation are expressed on or bound to endothelium (Fig. 2A). Normally, complement regulation remains intact even when the activities of one or two regulators are partially reduced. However, triggers, such as infections and pregnancy, that are associated with inflammation and complement activation may lead to problems in such persons,⁶⁴ since the vascular endothelium may require multiple regulators for protection. Certain vascular beds may be at increased risk. For example, the glomerular capillary bed has a fenestrated endothelium, which continually exposes the subendothelial matrix to a variety of circulating proteins and peptides. Thus, anyone lacking complement regulatory proteins is particularly vulnerable to complement attack. Persons with gain-of-function mutations in *C3* or *CFB* are similarly at risk, since these mutations lead to C3-convertase hyperactivity.

In the presence of events that enhance alternative-pathway activation, carriers of complement mutations undergo excess C3b formation and deposition on vascular endothelium. An uncontrolled level of C3 convertase leads to more C3b molecules and to more C5 convertase, initiating the formation of the membrane-attack complex. Complement-mediated endothelial injury creates a prothrombotic state through exposure of subendothelial collagen, von Willebrand factor, and fibrinogen (Fig. 2B). Moreover, it has been shown that mutant CFH has defective binding to platelets, allowing C3 and C9 deposition and platelet activation.⁶⁵

CLINICAL COURSE AND OUTCOME

Among patients with atypical hemolytic–uremic syndrome who have genetic mutations, 67% are affected during childhood,^{14,22} and the disease is diagnosed in almost all patients with anti-CFH antibodies before the age of 16 years.⁴⁹ Acute episodes manifest with severe hemolytic anemia, thrombocytopenia, and acute renal failure. Extrarenal (i.e., central nervous system or multivisceral) involvement occurs in 20% of patients.^{14,22}

Both short-term and long-term outcomes vary according to the underlying complement abnormality. About 60 to 70% of patients with *CFH*, *CFI*, or *C3* mutations and 30% of children with anti-CFH autoantibodies lose renal function or die during the presenting episode or have end-stage renal disease after relapses^{14,22} (Table 2). *CFB* mutations are associated with particularly poor renal outcomes, with a loss of renal function in 88% of patients in one study.¹⁷

About 20% of patients with *CFH* mutations have cardiovascular complications and excess mortality.²² Chronic complement dysregulation can contribute to the formation of atheromatous lesions.⁶⁶

N ENGLJ MED 361;17 NEJM.ORG OCTOBER 22, 2009

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

Long-term survival of patients with *CFH* mutations (50% at 10 years) is poorer than that of patients with *CFI* or *C3* mutations or anti-CFH autoantibodies (80 to 90% at 10 years^{14,22}).

Carriers of *MCP* mutations have a good prognosis, with a complete remission rate of 80 to 90% (Table 2). Recurrences are frequent, but the long-term outcome appears good, with 80% of patients remaining free of dialysis.^{14,22} Rarely, concurrent genetic abnormalities may lead to exceptionally severe disease.^{14,67}

TREATMENT

Early reports of successful treatment with plasma in atypical hemolytic-uremic syndrome date back 30 years.68,69 Since then, plasma exchange or infusion has been associated with a decrease in mortality from 50% to 25%.70,71 Guidelines suggest that plasma therapy should be started within 24 hours after diagnosis, with an exchange of one to two plasma volumes per day or an infusion of 20 to 30 ml per kilogram of body weight.72,73 (For details, see the case reports in the Supplementary Appendix.) Plasma exchange allows for the provision of larger amounts of plasma than would be possible with infusion while avoiding fluid overload. However, trials of plasma therapy in patients with the hemolytic-uremic syndrome are few and not current.74,75 A recent meta-analysis76,77 suggesting that plasma offers no significant benefit over simple supportive therapy may be misleading, since the trials that were evaluated did not distinguish between Stx-related and atypical hemolytic-uremic syndrome.74,75

Since CFH is a plasma protein, plasma infusion or exchange provides normal CFH to patients with homozygous mutations and complete CFH deficiency and induces disease remission (Table 2).14,22,78,79 However, since such patients are plasma-dependent, unresponsiveness may develop after long-term therapy.79-81 Carriers of heterozygous CFH mutations usually have normal levels of CFH, but half is dysfunctional. The beneficial effect of plasma strongly depends on the amount, frequency, and method of administration, with plasma exchange having been shown to be superior to plasma infusion for remission and prevention of recurrences, possibly through the removal of mutant dysfunctional CFH molecules^{82,83} (case reports in the Supplementary Appendix). Overall in patients with CFH mutations, either complete remission or partial remission (which was defined as hematologic normalization with renal sequelae) occurred in 60% of plasma-treated patients^{14,22} (Table 2).

Plasma exchange appears to be effective in removing anti-CFH antibodies.^{22,48} However, the effect is usually transient. The combination of plasma exchange with the use of immunosuppressant drugs (e.g., corticosteroids and azathioprine or mycophenolate mofetil) and an anti-CD20 antibody (rituximab) resulted in long-term dialysis-free survival in 60 to 70% of patients.^{49,51,84,85}

Patients with *CFI* mutations have only a partial response to plasma therapy; remission occurred in only 30 to 40% of patients.^{14,22,86} Since MCP is a cell-associated protein, plasma exchange or infusion is unlikely to be effective in patients with *MCP* mutations. Indeed, 80 to 90% of such patients have remission without plasma treatment.^{14,22,86} Plasma exchange or infusion resulted in a response in 30% of patients with *CFB* mutations and in 50% of those with *C3* mutations.^{17,18} Possibly, patients with either *CFB* or *C3* mutations need more frequent plasma exchanges to clear the hyperfunctional mutant CFB and C3 (Table 2).

TRANSPLANTATION

It has long been debated whether kidney transplantation is appropriate for the treatment of end-stage renal disease in patients with atypical hemolyticuremic syndrome. The disease recurs in around 50% of patients who undergo transplantation, and graft failure occurs in 80 to 90% of those with recurrent disease.87,88 The type of mutation may predict the outcome after transplantation (Table 2). The recurrence rate after transplantation is 70 to 90% in patients with genetic abnormalities in the circulating complement regulators CFH and CFI, mainly of hepatic origin.58,87,88 Intensive longterm plasma prophylaxis was thought to prevent recurrence in one patient with a CFH mutation⁸⁹ but failed in another patient.90 Atypical hemolyticuremic syndrome recurred in 40 to 50% of patients with C3 mutations.¹⁸ A patient with a CFB mutation who underwent renal transplantation had recurrence of disease.17

The outcome of single kidney transplantation is more favorable in patients with *MCP* mutations than in those with other mutations. More than 80% had no recurrence, with a rate of longterm graft survival that was similar to that of patients who underwent transplantation for other causes.^{22,87,88} The *MCP* gene product, membrane

N ENGLJ MED 361;17 NEJM.ORG OCTOBER 22, 2009

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

cofactor protein, is a transmembrane protein that is highly expressed in the kidney, so kidney transplantation, not surprisingly, corrects the defect.

Living-donor transplantation is contraindicated in patients with atypical hemolytic–uremic syndrome because of the high risk of recurrent disease.^{91,92} In addition, such procedures may be risky to donors, who may be mutation carriers. For example, de novo atypical hemolytic–uremic syndrome developed in a man with a heterozygous *CFH* mutation after he donated a kidney to his affected child.⁹² If living-donor transplantation is considered, the donor and recipient should undergo genotyping of complement genes to identify hitherto unsuspected mutation carriers.

Simultaneous kidney and liver transplantation was performed in two children with atypical hemolytic-uremic syndrome and CFH mutations with the rationale of correcting the genetic defect and preventing recurrence.93,94 However, both cases were complicated by early failure of the transplanted liver. The first child recovered after a second liver transplantation and had no symptoms of the hemolytic-uremic syndrome for 3 years but ultimately died from hepatic encephalopathy.93,95 This case offered the proof of concept that liver transplantation cures atypical hemolytic-uremic syndrome associated with CFH mutations. The second case was also complicated by failure of the transplanted liver, with concomitant widespread microvascular thrombosis and complement deposition.94 The investigators who reported the case speculated that surgical stress with ischemiareperfusion induced complement activation in the liver that could not be regulated because of functional CFH deficiency. A modified approach that included extensive plasma exchange before surgery to provide a sufficient amount of normal CFH until the liver graft recovered synthetic function was applied in eight subsequent cases95-97 and succeeded in seven; severe hepatic thrombosis and fatal encephalopathy developed in the eighth patient.95 Thus, the substantial risks of dual kidney and liver transplantation require a careful assessment of possible benefits for any candidate patient.

Screening for mutations may help patients and clinicians to make more informed decisions regarding listing for transplantation on the basis of the risk of recurrence. A position paper reporting the conclusions of a 2007 conference on atypical hemolytic–uremic syndrome⁹⁵ listed groups of patients for whom isolated kidney transplantation would be extremely risky and for whom combined kidney–liver transplantation would be worth considering. They also suggested which patients would be most likely to benefit from isolated kidney transplantation (Table 2).

EVOLVING APPROACHES

The identification of complement genetic abnormalities may facilitate treatments that down-regulate complement activation. A human plasmaderived CFH concentrate is being developed. (For details, see the European Medicines Agency Web site at www.emea.europa.eu/pdfs/human/comp/ opinion/52123506en.pdf.) A humanized anti-C5 monoclonal antibody, eculizumab, which had undergone phase 3 trials involving patients with paroxysmal nocturnal hemoglobinuria,98 was reported as promising in patients with atypical hemolyticuremic syndrome in two single-case reports.99,100 An 18-month-old boy with a plasma-resistant congenital form of the disease achieved remission after the initiation of treatment with eculizumab.99 although a possible effect of previous plasma therapy could not be ruled out because markers of hemolysis began to decrease before the administration of eculizumab. A 30-year-old woman with a CFH mutation who had a recurrence of the hemolytic-uremic syndrome in a kidney graft¹⁰⁰ had resolution of hemolysis and improved transplant function after receiving eculizumab. Results concerning 14 additional eculizumab-treated patients, 10 of whom achieved stable remission, have been reported recently (Nurnberger J: personal communication). The efficacy of eculizumab in the treatment of atypical hemolytic-uremic syndrome is being evaluated in controlled trials that are either ongoing or planned (ClinicalTrials. gov numbers, NCT00844545, NCT00844428, NCT00838513, and NCT00844844). (For details regarding international registries of patients and addresses of the main laboratories that perform genetic screening, see the Resources section in the Supplementary Appendix.)

SUMMARY

During the past decade, multiple and complex genetic abnormalities that are associated with atypical hemolytic–uremic syndrome have been described. Although of disparate origin, diseaseassociated abnormalities have in common the

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

overactivation of the alternative complement pathway, which has opened perspectives for complement inhibitor therapies in the future.

Supported in part by grants from Fondazione ART La Ricerca Sui Trapianti, Fondazione Aiuto Ricerca Malattie Rare, Istituto Superiore di Sanità, and the Telethon Foundation.

REFERENCES

1. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035-50.

2. Besbas N, Karpman D, Landau D, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocy-topenic purpura and related disorders. Kidney Int 2006;70:423-31.

 Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxinassociated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008;23:1749-60.
 Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004;43:976-82.

5. Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 1998;9:1126-33.

6. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60: 831-46.

7. Benz K, Amann K. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS)/thrombocytic thrombopenic purpura (TTP). Thromb Haemost 2009;101:265-70.

8. Campbell S, Carré JJ. Fatal haemolytic uraemic syndrome and idiopathic hyperlipaemia in monozygotic twins. Arch Dis Child 1965;40:654-8.

9. Kaplan BS, Chesney RW, Drummond KN. Hemolytic uremic syndrome in families. N Engl J Med 1975;292:1090-3.

10. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005;31:681-90.

11. Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int 2002; 62:1093-104.

12. Karthikeyan V, Parasuraman R, Shah V, Vera E, Venkat KK. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 2003;3:1289-94.

Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999;55:2457-66.
 Caprioli J, Noris M, Brioschi S, et al.

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108:1267-79.

15. Noris M, Brioschi S, Caprioli J, et al.

Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003;362:1542-7. **16.** Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003;100:12966-71.

17. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007;104:240-5. [Erratum, Proc Natl Acad Sci US 2007;104:10749.]

18. Frémeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112:4948-52.

19. Le Quintrec M, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008;8:1694-701.

20. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008;111:624-32.

21. Fakhouri F, Jablonski M, Lepercq J, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 2008;112: 4542-5.

22. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72.

23. Carreras L, Romero R, Requesens C, et al. Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3,B7 haplotype. JAMA 1981;245:602-4.

24. Stühlinger W, Kourilsky O, Kanfer A, Sraer JD. Haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet 1974;2:788-9.

25. Noris M, Ruggenenti P, Perna A, et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. J Am Soc Nephrol 1999;10:281-93.

26. Kim Y, Miller K, Michael AF. Breakdown products of C3 and factor B in hemolytic-uremic syndrome. J Lab Clin Med 1977;89:845-50.

Dr. Noris reports receiving consulting fees from Adienne. No other potential conflict of interest relevant to this article was reported.

We thank Drs. Mauro Abbate and Irene van der Meer for their help in the critical reading and preparation of this manuscript and Dr. Antonella Piccinelli for her contribution to the original figures.

> **27.** Barré P, Kaplan BS, de Chadarévian JP, Drummond KN. Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3. Arch Pathol Lab Med 1977;101:357-61.

> **28.** Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001;138:412-7.

29. Walport MJ. Complement: first of two parts. N Engl J Med 2001;344:1058-66.

30. Devaux P, Christiansen D, Fontaine M, Gerlier D. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur J Immunol 1999; 29:815-22.

31. Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981;46:110-9.

32. Rougier N, Kazatchkine MD, Rougier JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998;9:2318-26.

33. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998;53:836-44.

34. Richards A, Buddles MR, Donne RL, et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001;68:485-90.

35. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004;15:787-95.

36. Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001;12:297-307.

37. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003;12:3385-95.

38. Pérez-Caballero D, González-Rubio C, Gallardo ME, et al. Clustering of missense mutations in the C-terminal region of fac-

N ENGLJ MED 361;17 NEJM.ORG OCTOBER 22, 2009

1685

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

tor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001;68:478-84.
39. Zipfel PF, Skerka C. Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunol Today 1994;15:121-6.

40. Jokiranta TS, Jaakola VP, Lehtinen MJ, Pärepalo M, Meri S, Goldman A. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J 2006;25: 1784-94.

41. Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003;111: 1181-90.

42. Heinen S, Józsi M, Hartmann A, et al. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. J Am Soc Nephrol 2007; 18:506-14.

43. Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004;41:81-4.

44. Nan R, Gor J, Perkins SJ. Implications of the progressive self-association of wild-type human factor H for complement regulation and disease. J Mol Biol 2008;375: 891-900.

45. Pangburn MK, Rawal N, Cortes C, Alam MN, Ferreira VP, Atkinson MA. Polyanion-induced self-association of complement factor H. J Immunol 2009;182: 1061-8.

46. Heinen S, Sanchez-Corral P, Jackson MS, et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006;27:292-3.

47. Venables JP, Strain L, Routledge D, et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006;3(10):e431.

48. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-63.

49. Skerka C, Józsi M, Zipfel PF, Dragon-Durey MA, Fremeaux-Bacchi V. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 2009;101:227-32.
50. Dragon-Durey MA, Blanc C, Marliot F, et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009;46:447-50.
51. Józsi M, Strobel S, Dahse HM, et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in

hemolytic uremic syndrome. Blood 2007; 110:1516-8.

52. Józsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008;111:1512-4.
53. Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007;3(3):e41.

54. Koziolek MJ, Zipfel PF, Skerka C, et al. Chronic course of a hemolytic uremic syndrome caused by a deficiency of factor H-related proteins (CFHR1 and CFHR3). Kidney Int 2008;74:384-8.

55. Liszewski MK, Leung M, Cui W, et al. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem 2000; 275:37692-701.

56. Nakanishi I, Moutabarrik A, Hara T, et al. Identification and characterization of membrane cofactor protein (CD46) in the human kidneys. Eur J Immunol 1994; 24:1529-35.

57. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17:2017-25.

58. Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:2150-5.

59. Kavanagh D, Richards A, Noris M, et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008;45:95-105.

60. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41(6):e84.

61. Delvaeye M, Noris M, DeVriese A, et al. Thrombomodulin mutations in atypical hemolytic–uremic syndrome. N Engl J Med 2009;361:345-57.

62. Esparza-Gordillo J, Jorge EG, Garrido CA, et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006;43:1769-75.

63. Martinez-Barricarte R, Pianetti G, Gautard R, et al. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2008;19:639-46.

64. Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 2006; 43:68-77.

65. Ståhl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome con-

tributes to complement deposition on platelets and their activation. Blood 2008;111: 5307-15.

66. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 1989;9:802-11.

67. Fremeaux-Bacchi V, Sanlaville D, Menouer S, et al. Unusual clinical severity of complement membrane cofactor proteinassociated hemolytic-uremic syndrome and uniparental isodisomy. Am J Kidney Dis 2007;49:323-9.

68. Remuzzi G, Misiani R, Marchesi D, et al. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet 1978;2:871-2.

69. Remuzzi G, Misiani R, Marchesi D, et al. Treatment of the hemolytic uremic syndrome with plasma. Clin Nephrol 1979; 12:279-84.

70. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 1991;325:398-403.

71. George JN. How I treat patients with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Blood 2000; 96:1223-9.

72. Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009;24: 687-96.

73. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathies. In: Wilcox CS, ed. Therapy in nephrology & hypertension: a companion to Brenner & Rector's the kidney. 3rd ed. Philadelphia: Saunders, 2008:294-312.

74. Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J. Treatment of the childhood haemolytic uraemic syndrome with plasma: a multicentre randomized controlled trial. Pediatr Nephrol 1988:2:279-85.

75. Rizzoni G, Claris-Appiani A, Edefonti A, et al. Plasma infusion for hemolyticuremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112:284-90.

76. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;53:259-72.

77. Noris M, Remuzzi G. Thrombotic microangiopathy: what not to learn from a meta-analysis. Nat Rev Nephrol 2009;5: 186-8.

78. Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007;22:874-80.

79. Licht C, Weyersberg A, Heinen S, et al. Successful plasma therapy for atypical

N ENGLJ MED 361;17 NEJM.ORG OCTOBER 22, 2009

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.

hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005;45:415-21.

80. Nathanson S, Frémeaux-Bacchi V, Deschênes G. Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol 2001;16:554-6.
81. Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschênes G. Secondary failure of plasma therapy in factor H deficiency. Pediatr Nephrol 2006;21:1769-71.

82. Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 2008;23:1517-21.

83. Lapeyraque AL, Wagner E, Phan V, et al. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008;23:1363-6.

84. Dragon-Durey MA, Frémeaux-Bacchi V. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol 2005;27:359-74.

85. Kwon T, Dragon-Durey MA, Macher MA, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008;23:2088-90.

86. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic

uremic syndrome. J Am Soc Nephrol 2007; 18:2392-400.

87. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated haemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88-99.

88. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008;12:619-29.

89. Olie KH, Goodship TH, Verlaak R, et al. Posttransplantation cytomegalovirusinduced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis 2005;45(1):e12-e15.

90. Olie KH, Florquin S, Groothoff JW, et al. Atypical relapse of hemolytic uremic syndrome after transplantation. Pediatr Nephrol 2004;19:1173-6.

91. Chan MR, Thomas CP, Torrealba JR, et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis 2009;53:321-6.

92. Donne RL, Abbs I, Barany P, et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002;40(6):E22.

93. Remuzzi G, Ruggenenti P, Codazzi D, et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002;359:1671-2.

94. Remuzzi G, Ruggenenti P, Colledan M, et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation. Am J Transplant 2005;5: 1146-50.

95. Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009;20:940-9.

96. Saland JM, Emre SH, Shneider BL, et al. Favorable long-term outcome after liverkidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006;6:1948-52.

97. Jalanko H, Peltonen S, Koskinen A, et al. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 2008;8:216-21.

98. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal noc-turnal hemoglobinuria. Blood 2008;111: 1840-7.

99. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic–uremic syndrome. N Engl J Med 2009;360:544-6. **100.** Nürnberger J, Philipp T, Witzke O, Opazo Saez A, et al. Eculizumab for atypical hemolytic–uremic syndrome. N Engl J Med 2009;360:542-4. [Erratum, N Engl J Med 2009;360:2487.]

Copyright © 2009 Massachusetts Medical Society.

POWERPOINT SLIDES OF JOURNAL FIGURES AND TABLES

At the *Journal*'s Web site, subscribers can automatically create PowerPoint slides. In a figure or table in the full-text version of any article at **NEJM.org**, click on Get PowerPoint Slide. A PowerPoint slide containing the image, with its title and reference citation, can then be downloaded and saved.

1687

The New England Journal of Medicine

Downloaded from nejm.org at ADVOCATE LIBRARY NETWORK on February 12, 2016. For personal use only. No other uses without permission.